548 related articles for article (PubMed ID: 16140750)
1. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and protective efficacy of recombinant major envelope protein (rH3L) of buffalopox virus in animal models.
Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Shivachandra SB
Antiviral Res; 2016 Feb; 126():108-16. PubMed ID: 26723250
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
[TBL] [Abstract][Full Text] [Related]
5. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y
J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354
[TBL] [Abstract][Full Text] [Related]
6. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge.
Lustig S; Fogg C; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2005 Nov; 79(21):13454-62. PubMed ID: 16227266
[TBL] [Abstract][Full Text] [Related]
7. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
[TBL] [Abstract][Full Text] [Related]
9. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.
McCausland MM; Benhnia MR; Crickard L; Laudenslager J; Granger SW; Tahara T; Kubo R; Koriazova L; Kato S; Crotty S
Antivir Ther; 2010; 15(4):661-75. PubMed ID: 20587859
[TBL] [Abstract][Full Text] [Related]
11. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
12. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
[TBL] [Abstract][Full Text] [Related]
13. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine.
Benhnia MR; McCausland MM; Su HP; Singh K; Hoffmann J; Davies DH; Felgner PL; Head S; Sette A; Garboczi DN; Crotty S
J Virol; 2008 Apr; 82(7):3751-68. PubMed ID: 18234801
[TBL] [Abstract][Full Text] [Related]
14. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of recombinant major envelope proteins (rA27L and rH3L) of buffalopox virus provides enhanced immunogenicity and protective efficacy in animal models.
Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Pandey AB; Shivachandra SB
Antiviral Res; 2017 May; 141():174-178. PubMed ID: 28259752
[TBL] [Abstract][Full Text] [Related]
16. An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies.
Xu C; Meng X; Yan B; Crotty S; Deng J; Xiang Y
Virology; 2011 Sep; 418(1):67-73. PubMed ID: 21810533
[TBL] [Abstract][Full Text] [Related]
17. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
[TBL] [Abstract][Full Text] [Related]
18. Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox.
Kaever T; Matho MH; Meng X; Crickard L; Schlossman A; Xiang Y; Crotty S; Peters B; Zajonc DM
J Virol; 2016 May; 90(9):4334-4345. PubMed ID: 26889021
[TBL] [Abstract][Full Text] [Related]
19. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.
Shinoda K; Wyatt LS; Irvine KR; Moss B
Virol J; 2009 Mar; 6():28. PubMed ID: 19257896
[TBL] [Abstract][Full Text] [Related]
20. An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model.
Law M; Pütz MM; Smith GL
J Gen Virol; 2005 Apr; 86(Pt 4):991-1000. PubMed ID: 15784892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
